Uganda declares end to latest ebola outbreak
Kampala: Uganda on Saturday declared an end to the country's latest outbreak of ebola, three months after authorities confirmed cases of the highly infectious and often fatal viral hemorrhagic infection in the capital Kampala.
The East African country announced its latest outbreak on January 30 after the death of a male nurse who tested positive for the virus.
"Good news! The current ebola
Sudan Virus Disease
outbreak has officially come to an end," the health ministry said in a post on the X platform.
It added the declaration of the end of the outbreak followed 42 days "without a new case since the last confirmed patient was discharged."
In the post, the ministry did not give the latest total caseload recorded during the outbreak.
In early March when the ministry last reported on the caseload, it said at least ten cases had been recorded with two deaths.
Ebola infections are frequent in Uganda which has many tropical forests that are natural reservoirs for the virus.
The latest outbreak, caused by the Sudan strain of the virus which has no approved vaccine, was Uganda's ninth since the country recorded its first infection in 2000.
Uganda also neighbours the Democratic Republic of Congo which has recorded over a dozen outbreaks, including one in 2018-2020 that killed nearly 2,300 people. The outbreak started in Kampala, a crowded city of about four million that is also a crossroads for routes branching out to eastern Congo, Kenya, Rwanda and South Sudan.
Although outbreaks have been common, health experts say the country has been able to leverage on its experience battling the disease over the years to bring them under control relatively quickly.
Ebola is transmitted through contact with infected bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
a day ago
- Time of India
Africa should step up own vaccines, says cholera-hit Angola
Luanda: Africa should step up production of its own vaccines to deal with a range of health issues, Angola, battling hundreds of cholera deaths this year, said Wednesday. "To enable a strong and sustainable response to this crisis and future crises, it is essential to put production of medicines and vaccines on our continent," Angolan President Joao Lourenco, who also heads the African Union, told a videoconference with other African leaders, his office said. "Total dependence on external imports limits our ability to respond and compromises our health sovereignty," Lourenco said during a conference which included World Health Organization (WHO) director general Tedros Adhanom Ghebreyesus. More than 90 percent of vaccines, medicines, medical tests, and other essential health supplies used in Africa are imported, according to a report by the African Centre for Disease Control and Prevention (ACDCP) published in April. Several African countries are battling cholera outbreaks with Sudan, South Sudan, Democratic Republic of Congo and Angola among the worst hit. As of June 2, Angola had recorded more than 24,530 cases this year, with 718 deaths, according to the Angolan presidency. On May 27, the Sudanese health ministry reported 172 deaths from the disease in a single week in the war-torn country. Africa's dependence on imported health products has proven disastrous during previous epidemics, including Covid-19, Ebola, Marburg and mpox, the ACDCP report said. That leaves the continent at the mercy of global trade tensions, geopolitical disruption and logistical delays, it said. Public health emergencies have significantly increased in Africa, rising from 152 in 2022 to 213 in 2024, the report added.
Mint
26-05-2025
- Mint
No one's safe until everyone's safe: This covid mantra retains relevance
The covid crisis taught the world fundamental lessons about the importance of global cooperation to fight disease. But that cooperation is under strain, as are the conditions needed to sustain it. Future funding for health and science is being called into question, and cuts to development assistance by some traditional donors are casting doubt on our ability to prevent and respond to infectious diseases in the world's most fragile countries. To ensure future resilience to pandemics, these gaps must be filled. The key to success lies in strong, innovative new partnerships between multinational organizations, private- and public-sector institutions and civil society. We already know from recent experience that strong global partnerships work. Five years ago, we managed to overcome vaccine nationalism (the hoarding of limited supplies) in formulating the global response to covid. Also Read: The princess who built India's healthcare system Gavi, a global alliance of public, private and civil-society groups, partnered with the European Investment Bank Group, which is the financing arm of the European Union, owned by its 27 member states, to mobilize €600 million ($720 million) in donor funding toward the Covax initiative. Without this funding, Covax would not have been able to move at the speed and scale that ultimately delivered nearly two billion vaccine doses. More than 100 (mainly) developing countries benefited because we had the foresight to respond to the pandemic cooperatively. Nor were the benefits confined to these countries. Recall the mantra of the pandemic: 'No one is safe, until everyone is safe.' More widespread and prolonged shutdowns meant greater disruptions to supply chains and the global economy. The faster we could provide access to testing, monitoring and contact-tracing technologies, the better our ability to detect new variants of the virus and adapt accordingly. It was laboratory technicians in South Africa who first identified and called attention to the notorious Omicron variant. Also Read: Healthcare for all: Don't rely on insurance alone Recognizing the imperative to be even better prepared for the next pandemic, we have continued to build on this previous success. The European Investment Bank is providing Gavi with €1 billion in liquidity to accelerate access to vaccines for viruses with pandemic potential (such as Ebola) and to support routine vaccination against preventable diseases like measles, malaria and the human papillomavirus (HPV), which is globally a leading cause of cervical cancer. A new vaccine against tuberculosis could also be on the horizon. This innovative approach has also inspired others and catalysed their efforts. For example, the G7 development- finance institutions, together with the European Investment Bank, MedAccess, and the International Finance Corporation, are working on a new surge-funding instrument to mobilize vaccines, therapeutics, diagnostics and other medical goods that low- and lower-middle income countries will need to respond to future pandemics. Boosting regional vaccine production is a critical priority. Africa accounts for 20% of the world's population, but produces just 0.1% of the world's supply of vaccines. Building the continent's vaccine-manufacturing base is a key part of any strategy to strengthen overall pandemic preparedness. Here, too, the European Investment Bank's partnership and financial innovation are a game changer. Gavi's $1.2 billion African Vaccine Manufacturing Accelerator—backed by over €750 million from European governments, as well as institutions including the European Investment Bank—is designed to dismantle barriers to local vaccine production. To help Africa achieve vaccine sovereignty, the European Investment Bank is also directly financing production facilities in Ghana, South Africa, and Senegal, through the Institut Pasteur de Dakar. Also Read: PM-JAY: A successful model for both healthcare delivery and financial security By combining our expertise, the European Investment Bank-Gavi partnership helps countries build stronger health systems and improve their ability to respond to pandemics and save lives. As leaders of mission-driven organizations, we know that protecting global health demands bold action. By investing in innovation and ensuring that resources reach those who need them most, we can reduce the risk of future outbreaks, safeguard communities and create a world where health crises no longer derail lives and livelihoods. Viruses don't care about politics, visas, tariffs or wars. They respond to tough immune systems and effective vaccines. If we fail to ensure that all countries have the resources they need to identify new outbreaks and respond quickly, we will all be at risk. We cannot protect ourselves, our loved ones or our economies without global cooperation. Investing in innovative global health partnerships is our best defence against the next big outbreak, implying large returns in terms of worldwide stability and security. ©2025/Project Syndicate The author are, respectively, president of European Investment Bank and CEO of Gavi, the Vaccine Alliance.
United News of India
26-05-2025
- United News of India
Ethiopia reports first mpox case
Addis Ababa, May 26 (UNI) Ethiopia has recorded its first mpox case since the outbreak in Africa last year, the country's health authorities confirmed on Sunday. A 21-day-old infant has tested positive for mpox in Moyale town, near the Kenyan border, the Ethiopian Ministry of Health and Public Health Institute said in a joint statement. Noting that subsequent testing also confirmed that the child's mother is infected with the virus, the ministry said the child and his mother have been placed in quarantine. According to the ministry, both the child and his mother have not suffered any serious health problems so far and are currently in stable condition. It said coordinated efforts are underway to trace the source of the infection. As Ethiopia becomes the latest African country to report an mpox case, the total number of affected countries on the continent since the start of last year has now reached 26, according to the Africa Centres for Disease Control and Prevention (Africa CDC). The ministry said that since the onset of the mpox outbreak in Africa, it has implemented a series of coordinated measures aimed at preventing the virus from entering the East African nation while also establishing strategies to control its spread should it enter the country. It said an emergency coordination centre has been established at the Public Health Institute to facilitate such efforts. "The Ministry of Health, in collaboration with relevant stakeholders, wishes to emphasise its commitment to enhancing ongoing measures aimed at preventing and controlling the spread of the disease," it said. The ministry also urged anyone who has come into contact with individuals infected with the virus, as well as those exhibiting symptoms of mpox, to promptly seek appropriate medical care. Given that the virus has been reported only in a confined area, the ministry said the public should remain calm and maintain their usual daily routines while adhering to safety protocols outlined by health authorities. On Thursday, the Africa CDC announced that 25 mpox-affected African countries had reported more than 130,000 cases since the start of last year. Of these, 31,745 were confirmed, and about 1,774 related deaths were recorded. Mpox, formerly known as monkeypox, was first detected in laboratory monkeys in 1958. It is a rare viral disease transmitted through body fluids, respiratory droplets and contaminated materials. The infection often causes fever, rash and swollen lymph nodes. UNI XINHUA ARN
